Hemangio Journal

Blood cell ratios could aid in detecting splenic tumors and forecasting prognosis in dogs.

Published on: April 17, 2025

Transcriptome analysis identifies key genes and miRNAs as potential biomarkers and therapeutic targets.

Published on: March 14, 2025

MiRNAs are particularly promising as diagnostic biomarkers, offering a non-invasive method that could be integrated into routine bloodwork.

Published on: February 26, 2025

They hope these findings will help refine treatment strategies and improve outcomes.

Published on: January 22, 2025

Hemangiosarcoma can have a very heterogeneous cytologic appearance that can be used to support a suspected diagnosis

Published on: January 21, 2025

Techniques show promise for early, non-invasive detection of canine hemangiosarcoma through cfDNA fragmentation and CNAs using machine learning.

Published on: January 24, 2025

Weak PTEN and strong EGFR expressions were linked to high-grade tumors, with EGFR activation of the PI3K/AKT pathway suggesting potential targets for canine soft tissue sarcoma therapy.

Published on: January 20, 2025

The results confirmed a low frequency of malignant splenic lesions and HSA in dogs, with a majority of diagnoses being benign masses.

Published on: January 20, 2025

Study shows low prevalence of occult cancer in older dogs, with physical exams and cytology being key diagnostic methods.

Published on: December 18, 2024

Insights from a risk assessment and early detection test of naturally occurring cancers in companion dogs

Published on: December 16, 2024

Accurately counting mitotic figures (MFs) is key to tumor grading, but pathologists often struggle with consistency. New advances in digital pathology and deep learning could revolutionize MF detection.

Published on: December 18, 2024

This study explores how resveratrol supplementation may reduce chemotherapy-induced cardiac toxicity in dogs while enhancing anti-tumor effects in hemangiosarcoma.

Published on: December 23, 2024